PriceTargets.com logo

Tango Therapeutics - TNGX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $38.42
  • Forecasted Upside: 13.94%
  • Number of Analysts: 14
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$33.72 As of 06/17/2026 01:33 PM ET
▲ +1.556 (4.84%)

This chart shows the closing price for TNGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tango Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TNGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNGX

Analyst Price Target is $38.42
▲ +13.94% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Tango Therapeutics in the last 3 months. The average price target is $38.42, with a high forecast of $69.00 and a low forecast of $14.00. The average price target represents a 13.94% upside from the last price of $33.72.

This chart shows the closing price for TNGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 14 polled investment analysts is to moderate buy stock in Tango Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2026
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/17/2026
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/16/2026

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/12/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
6/9/2026HC WainwrightBoost TargetBuy ➝ Buy$27.00 ➝ $66.00
6/9/2026Canaccord Genuity GroupBoost TargetBuy ➝ Buy$30.00 ➝ $42.00
6/8/2026MizuhoSet Target$36.00
6/8/2026Wolfe ResearchSet TargetPeer Perform ➝ Outperform$35.00
6/8/2026B. Riley FinancialReiterated RatingBuy ➝ Buy
6/8/2026Leerink PartnersBoost TargetOutperform ➝ Outperform$55.00 ➝ $69.00
6/8/2026Wolfe ResearchUpgradePeer Perform ➝ Outperform
5/28/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
5/15/2026MizuhoBoost TargetOutperform ➝ Outperform$20.00 ➝ $30.00
5/14/2026Piper SandlerDowngradeOverweight ➝ Neutral$16.00 ➝ $24.00
5/14/2026UBS GroupSet Target$55.00
5/14/2026Jefferies Financial GroupDowngradeBuy ➝ Hold$18.00 ➝ $27.00
5/14/2026Leerink PartnersBoost TargetOutperform ➝ Outperform$28.00 ➝ $55.00
5/14/2026WedbushBoost TargetOutperform ➝ Outperform$19.00 ➝ $33.00
5/11/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
4/27/2026CitigroupReiterated RatingBuy ➝ Buy
4/27/2026Stifel NicolausBoost TargetBuy ➝ Buy$24.00 ➝ $40.00
4/20/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
4/2/2026Canaccord Genuity GroupInitiated CoverageBuy$30.00
3/27/2026B. Riley FinancialReiterated RatingBuy ➝ Buy
3/11/2026MizuhoBoost TargetOutperform ➝ Outperform$19.00 ➝ $20.00
3/9/2026Stifel NicolausBoost TargetBuy ➝ Buy$15.00 ➝ $24.00
3/6/2026WedbushBoost TargetOutperform ➝ Outperform$15.00 ➝ $19.00
3/6/2026GuggenheimBoost TargetBuy ➝ Buy$18.00 ➝ $20.00
3/6/2026HC WainwrightBoost TargetBuy ➝ Buy$13.00 ➝ $27.00
3/5/2026Jefferies Financial GroupReiterated RatingBuy ➝ Buy$18.00
2/23/2026MizuhoInitiated CoverageOutperform$19.00
2/6/2026GuggenheimBoost TargetBuy ➝ Buy$12.00 ➝ $18.00
1/21/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
1/16/2026Piper SandlerBoost TargetOverweight ➝ Overweight$11.00 ➝ $14.00
12/3/2025Stifel NicolausInitiated CoverageBuy$15.00
11/18/2025B. Riley FinancialBoost TargetBuy ➝ Buy$8.00 ➝ $14.00
11/18/2025Wolfe ResearchInitiated CoveragePeer Perform
10/27/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
10/24/2025GuggenheimBoost TargetBuy ➝ Buy$10.00 ➝ $12.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/18/2025Piper SandlerInitiated CoverageOverweight ➝ Overweight$11.00
8/6/2025GuggenheimBoost TargetBuy ➝ Buy$8.00 ➝ $10.00
4/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
12/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
11/11/2024B. Riley FinancialLower TargetBuy ➝ Buy$16.00 ➝ $8.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
11/7/2024GuggenheimLower TargetBuy ➝ Buy$18.00 ➝ $8.00
10/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
9/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
8/8/2024WedbushBoost TargetOutperform ➝ Outperform$11.00 ➝ $13.00
7/17/2024Jefferies Financial GroupInitiated CoverageBuy$19.00
7/9/2024Cantor FitzgeraldReiterated RatingOverweight
7/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
5/28/2024GuggenheimUpgradeStrong-Buy
5/28/2024HC WainwrightLower TargetBuy ➝ Buy$16.00 ➝ $13.00
5/24/2024GuggenheimLower TargetBuy ➝ Buy$16.00 ➝ $14.00
5/24/2024BarclaysLower TargetOverweight ➝ Overweight$18.00 ➝ $13.00
5/23/2024WedbushLower TargetOutperform ➝ Outperform$18.00 ➝ $11.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00
4/4/2024Cantor FitzgeraldInitiated CoverageOverweight
3/20/2024HC WainwrightBoost TargetBuy ➝ Buy$16.00 ➝ $17.00
3/18/2024WedbushReiterated RatingOutperform$18.00
2/12/2024Piper SandlerInitiated CoverageOverweight$18.00
12/8/2023B. Riley FinancialInitiated CoverageBuy$16.00
8/11/2023HC WainwrightBoost Target$11.00 ➝ $16.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00
3/28/2023HC WainwrightBoost TargetBuy$10.00 ➝ $11.00
11/16/2022WedbushBoost Target$21.00
10/20/2022HC WainwrightUpgradeNeutral ➝ Buy
9/20/2021Leerink PartnersInitiated CoverageOutperform
9/7/2021WedbushInitiated CoverageOutperform
9/7/2021GuggenheimInitiated CoverageBuy$16.00
9/7/2021The Goldman Sachs GroupInitiated CoverageBuy$17.00
(Data available from 6/17/2021 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 4 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 6 very negative mentions
Mentions as of
6/17/2026

Current Sentiment

  • 4 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 6 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Tango Therapeutics logo
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $33.72
Low: $31.52
High: $34.39

50 Day Range

MA: $23.89
Low: $19.65
High: $32.90

52 Week Range

Now: $33.72
Low: $4.60
High: $34.39

Volume

945,120 shs

Average Volume

3,532,853 shs

Market Capitalization

$4.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Tango Therapeutics?

The following Wall Street research analysts have issued stock ratings on Tango Therapeutics in the last twelve months: B. Riley Financial, Inc., Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Leerink Partners, Mizuho, Piper Sandler, Stifel Nicolaus, UBS Group AG, Wall Street Zen, Wedbush, Weiss Ratings, and Wolfe Research.
View the latest analyst ratings for TNGX.

What is the current price target for Tango Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Tango Therapeutics in the last year. Their average twelve-month price target is $38.42, suggesting a possible upside of 13.9%. Leerink Partners has the highest price target set, predicting TNGX will reach $69.00 in the next twelve months. B. Riley Financial, Inc. has the lowest price target set, forecasting a price of $14.00 for Tango Therapeutics in the next year.
View the latest price targets for TNGX.

What is the current consensus analyst rating for Tango Therapeutics?

Tango Therapeutics currently has 1 sell rating, 2 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TNGX.

What other companies compete with Tango Therapeutics?

Other companies that are similar to Tango Therapeutics include Viatris, Genmab A/S, Ascendis Pharma A/S, BridgeBio Pharma and Axsome Therapeutics. Learn More about companies similar to Tango Therapeutics.

How do I contact Tango Therapeutics' investor relations team?

Tango Therapeutics' physical mailing address is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company's listed phone number is 857-320-4900 and its investor relations email address is [email protected]. The official website for Tango Therapeutics is www.tangotx.com. Learn More about contacing Tango Therapeutics investor relations.